ライフサイエンスコーパス: event-free survival rate

1 The primary end point was the five-year event-free survival rate.

2 a result, had a significantly lower cardiac event-free survival rate.

3 ripheral-blood alpha-L-iduronidase activity (event-free survival rate, 85 percent).

4 Currently, the event-free survival rate after allogeneic-matched siblin

5 ative coronary stenting resulted in a higher event-free survival rate and a lower probability of repe

6 The 5-year event-free survival rate and risk of relapse in obese ve

7 was universally fatal, but current long-term event-free survival rates are nearly 80%.

8 The projected event-free survival rate at 24 months is 88%, and all pa

9 The event-free survival rate at 6-month follow-up was 91% in

10 The cardiac event-free survival rates at 1, 2 and 3 years were 99.2%

11 Event-free survival rates at 3 years in patients without

12 gap in prognosis was abolished in study XV: event-free survival rates at 5 years were 86.4% +/- 5.2%

13 Over the 8-year follow-up, cardiovascular event-free survival rates based on CRP levels above or b

14 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

15 oid leukemia (AML) have significantly higher event-free survival rates compared to those with non-DS

16 val rate was 86.7% at 5 years, with a 5-year event-free survival rate decreasing progressively to 50.

17 The main study endpoint was the event-free survival rate defined as freedom from target

18 ninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in te

19 The primary outcome was one-year event-free survival rate for the combined end point of d

20 The 72-month event-free survival rate for the composite end point of

21 The 3-year event-free survival rate for these patients was 58%.

22 Event-free survival rates for cardiovascular events were

23 With current treatment regimens, event-free survival rates for childhood acute lymphoblas

24 The 5-year event-free survival rates for patients with stages 0 to

25 The estimated 5-year overall survival and event-free survival rates for the entire group were 80%

26 The 5-year event-free survival rate (freedom from death, myocardial

27 As the overall long-term event-free survival rate in children with acute lymphobl

28 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

29 Event-free survival rates in noninducible and inducible

30 onserving strategies at 20 years, the breast event-free survival rate (no invasive cancer or DCIS) wa

31 No improvements in event-free survival rates occurred with successive coope

32 atients remained relapse free, with a 2-year event-free survival rate of 50% +/- 8%.

33 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

34 tained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval

35 te a 98% overall survival rate and a 6-month event-free survival rate of 78% (six target vessel revas

36 At 1 year, survival was 98%, with an event-free survival rate of 80%, reflecting predominantl

37 was 90.9% (95% CI, 83.9% to 95.0%), with an event-free survival rate of 87.8% (95% CI, 81.1% to 92.4

38 ars are 88%, 88%, and 77%, with an estimated event-free survival rate of only 30% at 15 years.

39 rcent, respectively (P<0.001), and five-year event-free survival rates of 56 percent and 44 percent (

40 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

41 s with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P < .001

42 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

43 temporary treatments have resulted in 5-year event-free survival rates of approximately 80% for child

44 The significantly higher event-free survival rates of Down syndrome (DS) children

45 The high event-free survival rates of Down syndrome (DS) children

46 evel in children with ALL, securing a higher event-free survival rate overall.

47 The estimated 5-year event-free survival rate (+/- SE) for patients with TEL

48 emia (ALL), dexamethasone resulted in higher event-free survival rates than prednisone, presumably du

49 The mean (+/-SE) event-free survival rate three years after the first ran

50 The event-free survival rate three years after the second ra

51 The event-free survival rate to hospital discharge was 90%.

52 , over a median of 3 years of follow-up, the event-free survival rate was 100%, and no patients recei

53 The event-free survival rate was 61%, 54% and 47% at one, tw

54 The event-free survival rate was 65.8% in the SES group and

55 For patients with PM, 5-year event-free survival rate was 73% (95% CI, 68% to 79%), a

56 The event-free survival rate was 80 +/- 1.5% at 1 year, 71 +

57 2-year event-free survival rate was 81% (95% CI 64-90).

58 rall survival rate was 93.3% +/- 7%, and the event-free survival rate was 86.7% +/- 9.5% for the obse

59 During a median of 5 years of follow-up, the event-free survival rate was 93%, and the overall surviv

60 After 3 years, the event-free survival rate was 94% (95% confidence interva

61 went transplantation, the 3-year overall and event-free survival rates were 52.5% and 44.2%, respecti

62 actuarial survival, response, and actuarial event-free survival rates were 62%, 48%, and 27%, respec

63 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

64 The 1- and 2-year cumulative event-free survival rates were 87% and 81%.

65 Two-year event-free survival rates were 97% in the ATRA-arsenic t

66 splant-related mortality (TRM), relapse, and event-free survival rates were analyzed.

67 Remission induction, survival, and event-free survival rates were not significantly differe

68 t years have not translated into an improved event-free survival rate, which continues to be influenc

69 Better event-free survival rates with second-generation TKI the